This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound ~~Compounds~~ of ~~the~~ formula I



I

wherein ~~in which~~

R is ~~denotes~~ H, A, A-CO-, Hal, -C≡C-H, -C≡C-A_2 or -C≡C-C(=O)-A,

R^1 is ~~denotes~~ H, =O, Hal, A, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA_x or $=CF_2$,

Ph is ~~denotes~~ phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA_x or Hal,

R^2 is ~~denotes~~ H, Hal_x or A,

R^3 is ~~denotes~~ a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is ~~may be~~ unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NR^4R^5, =NH, =N-OH, =N-OA_x and/or carbonyl oxygen (=O),
or $CONR^4R^5$,

R^4, R^5, independently of one another, are ~~denote~~ H or A,

R^4 and R^5 together may also be ~~denote~~ an alkylene chain having 3, 4 or 5 C atoms, which is optionally ~~may also be~~ substituted by A, Hal, OA_x and/or carbonyl oxygen (=CO),

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2, 3 or 4,

or a ~~and~~ pharmaceutically usable derivative, salt, solvate or stereoisomer ~~derivatives, salts, solvates and stereoisomers~~ thereof, including mixtures thereof in all ratios.

2. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein ~~in which~~ R is ~~denotes~~ Hal or -C≡C-H, ~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein ~~in which~~

R^3 is $CONR^4R^5$ or ~~denotes~~ a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is ~~may be~~ unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, $=NH_x$ and/or carbonyl oxygen (=O), and

~~or $CONR^4R^5$~~

R^4 and R^5 ~~R^4, R^5,~~ independently of one another, are each ~~denote~~ H or A, or R^4 and R^5 together are ~~also denote~~ an alkylene chain having 3, 4 or 5 C atoms~~,~~

~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~

R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, 4*H*-1,4-oxazin-4-yl, furyl, thienyl,

pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, or pyrazinyl, which in each case is optionally mono- or disubstituted by Hal and/or A, or is $CONR^4R^5$, and

R^4, R^5, independently of one another, are each ~~denote~~ H or A, or R^4 and R^5 together U ~~also~~ ~~denote~~ an alkylene chain having 3, 4 or 5 C atoms~~,~~

~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~

R^1 is ~~denotes~~ H, =O, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-, and

Ph is ~~denotes~~ unsubstituted phenyl~~,~~

~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~

R is ~~denotes~~ Hal or -C≡C-H,

R^1 is ~~denotes~~ H, =O, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-,

Ph is ~~denotes~~ unsubstituted phenyl,

R^2 is ~~denotes~~ H, Hal or A,

R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, 4*H*-1,4-oxazin-4-yl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl,

oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, or pyrazinyl, which in each case is optionally mono- or disubstituted by Hal and/or A, or is $CONR^4R^5$, and R^4 and R^5 ~~R^4, R^5~~; are each, independently of one another, ~~denote~~ H or A, or R^4 and R^5 together are ~~also denote~~ an alkylene chain having 3, 4 or 5 C atoms, ~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

7. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~ R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxo-piperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl, which in each case is optionally mono- or disubstituted by Hal and/or A, ~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

8. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~ R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl, ~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

9. (Currently Amended): A compound ~~Compounds~~ according to claim 1,

wherein ~~in which~~

R is ~~denotes~~ Hal or -C≡C-H,

R^1 is ~~denotes~~ H, =O, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-,

Ph is ~~denotes~~ unsubstituted phenyl,

R^2 is ~~denotes~~ H, Hal or A,

R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl,

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I, and

n is ~~denotes~~ 0, 1, 2, 3 or ~~4,~~

~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

10. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein said compound is: ~~selected from the group~~

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxopiperidin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-oxopyrrolidinyl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(2-oxopyrrolidinyl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)-phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)-phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-oxopyrrolidinyl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxopyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxopiperidinyl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1,3-oxazinan-3-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-acetoxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-benzylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-benzoyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-*tert*-butylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-isobutylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-cyclohexylmethylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-cyclopentylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-cyclopropylmethylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-cyclobutylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

or a ~~and~~ pharmaceutically usable derivative, salt, solvate or stereoisomers ~~derivatives, salts, solvates and stereoisomers~~ thereof, including mixtures thereof in all ratios.

11. (Currently Amended): A process ~~Process~~ for the preparation of a compound ~~compounds of the formula I~~ according to claim 1, said process comprising: ~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, characterised in that~~

a) reacting a compound of ~~the~~ formula II



II

~~in which R has the meaning indicated in Claim 1, is reacted~~ with a chloroformate derivative to give an intermediate carbamate derivative, which is subsequently reacted with a compound of ~~the~~ formula III-1



III-1

~~in which~~

~~R^1, R^2 and R^3 have the meaning indicated in Claim 1,~~

~~and,~~ wherein if R^1 is ~~denotes~~ OH, the OH group is optionally in protected form,

and subsequently~~, if desired,~~ optionally removing the OH-protecting group ~~is removed~~,

or

b) reacting a compound of the formula IV



IV,

~~in which R^2 and R^3 have the meaning indicated in Claim 1,~~

~~is reacted~~ with a chloroformate derivative to give an intermediate carbamate derivative, which is subsequently reacted with a compound of ~~the~~ formula III-2



III-2

~~in which R and R^1 have the meaning indicated in Claim 1,~~

~~and,~~ wherein if R^1 is ~~denotes~~ OH, the OH group is optionally in protected form,

and subsequently~~, if desired,~~ optionally removing the OH-protecting group ~~is removed~~,

and/or

(c) converting a base or acid of the formula I ~~is converted~~ into one of its salts.

12. (Currently Amended): A method of inhibiting coagulation factor Xa comprising using a compound ~~Compounds of the formula I~~ according to claim 1 as an inhibitor ~~inhibitors~~ of coagulation factor Xa.

13. (Currently Amended): A method of inhibiting coagulation factor VIIa comprising using a compound ~~Compounds of the formula I~~ according to claim 1 as an inhibitor ~~inhibitors~~ of coagulation factor VIIa.

14. (Currently Amended): A pharmaceutical composition ~~Medicaments~~ comprising at least one compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and ~~optionally~~ one or more excipients and/or adjuvants.

15. (Currently Amended): A pharmaceutical composition ~~Medicaments~~ comprising at least one compound of the formula I according to claim 1 ~~and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and at least one further medicament active ingredient.

16. (Currently Amended): A method of treating a patient suffering from ~~Use of compounds according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of~~ thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim 1.

17 (Currently Amended): A kit comprising ~~Set (kit) consisting of~~ separate packs of:

(a) an effective amount of a compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~,

and

(b) an effective amount of a further medicament active ingredient.

18. (Currently Amended): A method of preparing a pharmaceutical composition

for treating patient suffering from ~~Use of compounds of the formula I according to claim 1 and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of~~ thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, ~~in combination~~ said method comprising combining a compound according to claim 1 with at least one further medicament active ingredient.

19. (Currently Amended): A compound ~~Intermediate compounds~~ of ~~the~~ formula III-1



III-1

wherein ~~in which~~

R^1 is ~~denotes~~ H, =O, Hal, A, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, or $=CF_2$,

Ph is ~~denotes~~ phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA_s or Hal,

R^2 is ~~denotes~~ H, Hal or A,

R^3 is ~~denotes~~ a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is ~~may be~~ unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NR^4R^5, =NH, =N-OH, =N-OA_s and/or carbonyl oxygen (=O),

$CONR^4R^5$,

R^4 and R^5 are each ~~R^4, R^5~~, independently of one another, ~~denote~~ H or A, or R^4 and R^5 together ~~also denote~~ are an alkylene chain having 3, 4 or 5 C atoms, which is optionally ~~may~~

~~also be~~ substituted by A, Hal, OA and/or carbonyl oxygen (=CO),

R^6 is ~~denotes~~ an OH-protecting group,

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2, 3 or 4,

or an isomer or salt ~~and isomers and salts~~ thereof.

20. (Currently Amended): A compound ~~Intermediate compounds~~ according to Claim 19, wherein ~~in which~~

R^1 is ~~denotes~~ H, =O, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO- or cycloalkyl-$(CH_2)_n$-COO-,

Ph is ~~denotes~~ unsubstituted phenyl,

R^2 is ~~denotes~~ H, Hal or A,

R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl,

R^6 is ~~denotes~~ an OH-protecting group,

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2, 3 or 4,

or an isomer or salt ~~and isomers and salts~~ thereof.

21. (Currently Amended): A compound ~~Intermediate compounds~~ according to Claim 20, wherein ~~in which~~

R^1 is ~~denotes~~ H, =O, or OR^6,

R^2 is ~~denotes~~ H, Hal, or A,

R^3 is ~~denotes~~ 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl,

R^6 is ~~denotes~~ an alkylsilyl protecting group,

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2, 3 or 4,

or an isomer or salt ~~and isomers and salts~~ thereof.

22. (Currently Amended): A compound ~~Intermediate compounds~~ of ~~the~~ formula III-2



III-2

wherein ~~in which~~

R is ~~denotes~~ H, A, A-CO-, Hal, -C≡C-H, -C≡C-A_2 or -C≡C-C(=O)-A,

R^1 is ~~denotes~~ H, =O, Hal, A, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or $=CF_2$,

Ph is ~~denotes~~ phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA or Hal,

R^6 is ~~denotes~~ an OH-protecting group,

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2, 3 or 4,

where, if R^1 is ~~denotes~~ H, R is not ~~does not denote~~ Cl,

or an isomer or salt ~~and isomers and salts~~ thereof.

23. (Currently Amended): A compound ~~Intermediate compounds~~ according to Claim 22, wherein ~~in which~~

R is ~~denotes~~ Hal or -C≡C-H,

R^1 is ~~denotes~~ H, =O, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-,

Ph is ~~denotes~~ phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, or Hal,

R^6 is ~~denotes~~ an OH-protecting group,

A is ~~denotes~~ unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally ~~may also be~~ replaced by F or ~~and/or~~ chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2, 3 or 4,

where, if R^1 is ~~denotes~~ H, R is not ~~does not denote~~ Cl,

or an isomer or salt ~~and isomers and salts~~ thereof.

24 ~~23~~. (Currently Amended): A compound ~~Intermediate compounds~~ according to Claim 22, wherein ~~in which~~

R is ~~denotes~~ Hal or -C≡C-H,

R^1 is ~~denotes~~ H, =O, or OR^6,

R^6 is ~~denotes~~ an alkylsilyl protecting group,

Hal is ~~denotes~~ F, Cl, Br or I,

where, if R^1 is ~~denotes~~ H, R is not ~~does not denote~~ Cl,

or an isomer or salt ~~and isomers and salts~~ thereof.

25 24. (Currently Amended): A compound ~~Intermediate compounds~~ of ~~the~~ formula VI



VI

wherein ~~in which~~

R^1 is ~~denotes~~ OH or OR^6,

R^6 is ~~denotes~~ a silyl protecting group,

R^7 is ~~denotes~~ *tert*-butyloxycarbonyl (BOC) or benzyloxycarbonyl (Z),

or an isomer ~~and isomers~~ thereof.

26 ~~25~~. (Currently Amended): A process ~~Process~~ for the preparation of a compound ~~compounds~~ of ~~the~~ formula VI



VI

wherein ~~in which~~

R^1 is ~~denotes~~ OH or OR^6,

R^6 is ~~denotes~~ a silyl protecting group,

R^7 is ~~denotes~~ *tert*-butyloxycarbonyl (BOC) or benzyloxycarbonyl (Z),

or an isomer ~~and isomers~~ thereof, said process comprising:

reacting ~~obtainable by reaction of~~ a compound of ~~the~~ formula VII

$$R^7\text{-}NHNH_2 \qquad \text{VII},$$

wherein ~~in which~~ R^7 is ~~denotes~~ *tert*-butyloxycarbonyl ~~BOC~~ or benzyloxycarbonyl ~~Z~~, with silyl-protected 1,3-dibromopropan-2-ol, and optionally subsequently removing ~~subsequent removal of~~ the protecting group.